Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg,

Brivaracetam Tablets is a generic equivalent of Briviact Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of UCB Inc.

The product will be manufactured at Lupin’s facility in Nagpur, India.

Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, (RLD Briviact) had estimated annual sales of $420 million in the U.S. (IQVIA MAT September 2022).

USFDA approves Gene Therapy for Bladder Cance

USFDA approves this lung cancer drug

USFDA gives nod for Silodosin, Pregabalin Capsules

USFDA gives final approval for Desonide cream

USFDA gives nod for Diclofenac Sodium topical solution

USFDA gives approval for Venlafaxine ER tablets

NPPA fixes Retail Price of 12 scheduled formulations: December 2022

NPPA revises Retail Price of 107 scheduled formulations: December 2022

NABL asks Testing Laboratories to get product based accreditation

Goa FDA allows manufacture and marketing of Ulipristal Acetate Tablets 5mg

Drug Regulators sought Pharmacovigilance (PV) for Gabapentin and Pregabalin

Gujarat FDCA recovers more than Rs. 80 crore in DPCO violations

DCOIWA: Workshop on Medical Device Regulation and Legal Documentation organized

DCGI approves this Pneumococcal Conjugate Vaccine

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/21/usfda-gives-approval-for-brivaracetam-tablets/